Cite

HARVARD Citation

    Bräutigam, J. et al. (2019). Narciclasine inhibits angiogenic processes by activation of Rho kinase and by downregulation of the VEGF receptor 2. Journal of molecular and cellular cardiology. pp. 97-108. [Online]. 
  
Back to record